Company Filing History:
Years Active: 2025
Title: Nam Hui Kim: Innovator in Medical Research
Introduction: Nam Hui Kim is an inventor based in Daegu, South Korea. He has made significant contributions to the field of medical research, particularly in the development of novel compounds for therapeutic applications. Although he currently holds no granted patents, his work is noteworthy for its potential impact on treating various diseases.
Latest Patent Applications: Nam Hui Kim has filed several patent applications that focus on innovative small-molecule compounds. One of his latest applications is titled "New Small-Molecule Compounds for Controlling Endosomal Toll-Like Receptors and Therapeutic Agent for Autoimmune Diseases Using Same." This application discloses antagonistic small-molecule compounds that inhibit endosomal Toll-like receptors (TLRs). The compounds have shown promising results in preventing TNF-α secretion and inhibiting the production of inflammatory cytokines in a systemic lupus erythematosus animal model. Another significant application is for a "3-((8-((1H-PYRAZOL-4-YL)AMINO)IMIDAZO[1,2-A]PYRIDIN-3-YL)ETHINYL)-N-PHENYLBENZAMIDE Derivative." This invention relates to a pharmaceutical composition that can effectively inhibit the proliferation of cancer cells by targeting specific kinases.
Conclusion: Nam Hui Kim is an innovative researcher whose work in developing small-molecule compounds holds promise for advancing medical treatments. His contributions to the field are expected to pave the way for future breakthroughs in the management of autoimmune and cancer-related diseases.